Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data demonstrating compelling complete response rate in third-line or ...

Elfabrio (R) (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed diagnosis of Fabry disease (deficiency of ...

The Wide Bandgap Semiconductor Market is gaining strong momentum due to rising demand for energy-efficient power devices ...

Ironwood Pharmaceuticals, Inc. , a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced ...

Explains how FEMA empowers RBI to approve cross-border M&A while ensuring foreign exchange control, financial stability, and alignment with economic ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Enhancing Patient-Centric Care Through Oral Liquid Drug Delivery Formulations Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and ...

Anti-slip Additives Market to reach USD 762.9 Mn by 2035 at 4.6% CAGR, driven by rising workplace safety regulations and ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter ...

Single-use plastics (SUPs) are a major concern in countries such as the Philippines due to SUPs’ extensive use and ...

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...